Atossa Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $7.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar has given her Buy rating due to a combination of factors including Atossa Therapeutics’ recent advancements in the clinical and regulatory development of Z-endoxifen. The company is actively engaging with the FDA to explore an accelerated regulatory pathway for Z-endoxifen, which could potentially expedite its market entry and reduce associated trial costs. Furthermore, Atossa’s strategic amendments to their Phase 2 EVANGELINE trial are expected to streamline the study process, allowing for quicker data readouts and extending the company’s financial resources.
Additionally, Atossa has strengthened its leadership team to support the transition from clinical development to commercialization. New appointments, such as Janet R. Rea as Senior Vice President of R&D and Mark Daniel as Chief Financial Officer, bring valuable expertise to the company. These leadership changes, along with the promising clinical progress in trials like RECAST DCIS, position Z-endoxifen for significant growth opportunities in the breast cancer treatment market. The upcoming presentations at the SABCS will further showcase the safety and efficacy of Z-endoxifen, reinforcing the potential for its successful development and commercialization.